AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.00 Decreased By ▼ -0.53 (-0.41%)
BOP 6.76 Increased By ▲ 0.08 (1.2%)
CNERGY 4.50 Decreased By ▼ -0.13 (-2.81%)
DCL 8.70 Decreased By ▼ -0.24 (-2.68%)
DFML 41.00 Decreased By ▼ -0.69 (-1.66%)
DGKC 81.30 Decreased By ▼ -2.47 (-2.95%)
FCCL 32.68 Decreased By ▼ -0.09 (-0.27%)
FFBL 74.25 Decreased By ▼ -1.22 (-1.62%)
FFL 11.75 Increased By ▲ 0.28 (2.44%)
HUBC 110.03 Decreased By ▼ -0.52 (-0.47%)
HUMNL 13.80 Decreased By ▼ -0.76 (-5.22%)
KEL 5.29 Decreased By ▼ -0.10 (-1.86%)
KOSM 7.63 Decreased By ▼ -0.77 (-9.17%)
MLCF 38.35 Decreased By ▼ -1.44 (-3.62%)
NBP 63.70 Increased By ▲ 3.41 (5.66%)
OGDC 194.88 Decreased By ▼ -4.78 (-2.39%)
PAEL 25.75 Decreased By ▼ -0.90 (-3.38%)
PIBTL 7.37 Decreased By ▼ -0.29 (-3.79%)
PPL 155.74 Decreased By ▼ -2.18 (-1.38%)
PRL 25.70 Decreased By ▼ -1.03 (-3.85%)
PTC 17.56 Decreased By ▼ -0.90 (-4.88%)
SEARL 78.71 Decreased By ▼ -3.73 (-4.52%)
TELE 7.88 Decreased By ▼ -0.43 (-5.17%)
TOMCL 33.61 Decreased By ▼ -0.90 (-2.61%)
TPLP 8.41 Decreased By ▼ -0.65 (-7.17%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.60 Decreased By ▼ -2.72 (-4.44%)
UNITY 27.51 Increased By ▲ 0.08 (0.29%)
WTL 1.41 Increased By ▲ 0.03 (2.17%)
BR100 10,450 Increased By 43.4 (0.42%)
BR30 31,209 Decreased By -504.2 (-1.59%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)

BRUSSELS: Belgium has agreed to buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry told Reuters in an emailed statement on Monday.

Governments around the world are scrambling to buy Paxlovid, the pill developed by Pfizer.

Molnupiravir, jointly developed by Merck with Ridgeback Biotherapeutics, faces setbacks after disappointing trial data and France said in December it had cancelled its order for the drug..

Belgium's health minister said in early December that the government was in talks with Merck to buy molnupiravir, and Belgian health authorities had advised that both molnupiravir and Paxlovid should be purchased.

"Both talks are finalised and we will buy 10,000 of both," Arne Brinckman, a spokesman for the Belgian health ministry told Reuters on Monday, when asked about the possible purchase of courses of both treatments.

Pfizer's regimen is three pills in the morning and three pills at night. Merck's drug is taken as four pills in the morning and four at night.

Britain approves Pfizer's antiviral COVID-19 pill

The EU drug regulator has not authorised either, but has issued advice on how to use both as emergency treatments, as the bloc grapples with an exponential rise in cases driven by the highly contagious Omicron variant of the coronavirus.

The spokesman did not reply to a request to indicate how much Belgium had agreed to pay, and did not say when the country expected to receive the first courses.

Late in December France said it had cancelled its order for 50,000 courses of molnupiravir after the company released data in late November suggesting its drug was markedly less effective than thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30% .

Pfizer said Paxlovid showed near 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.

Comments

Comments are closed.